Yanmei Lu, PhD

VP of Biomarker and BioAnalytical Sciences
Sangamo Therapeutics
Richmond

Dr. Yanmei Lu is currently the Vice President of Biomarker and BioAnalytical Sciences at Sangamo Therapeutics. The functions of her group include biomarker discovery, biomarker strategy, bioanalysis and companion diagnostic development to support gene and cell therapy programs at both preclinical and clinical stages. Prior to joining Sangamo, Dr. Lu acquired extensive experience at Genentech in developing PK, biomarker, immunogenicity and functional assays for antibody screening, candidate selection and in vivo studies to evaluate PK/PD, efficacy and safety of large molecule therapeutics in disease areas of Neurosciences, Immunology, Oncology and Ophthalmology. Dr. Lu holds a PhD in Biochemistry and Molecular Biology from University of South Florida and has published over 40 peer-reviewed articles/book chapters.

Disclosure information not submitted.

Presentation(s):

• Anti-AAV Pre-Existing Antibody Assays for Patient Enrollment: Format, Concordance and Clinical Sensitivity

  Monday, October 17, 2022
  9:00 AM – 9:30 AM ET

• Qualified RT-qPCR Assays to Measure Transgene and Target Gene Expression

  Monday, October 17, 2022
  3:00 PM – 3:15 PM ET